Next Article in Journal
Auranofin, an Anti-Rheumatic Gold Compound, Modulates Apoptosis by Elevating the Intracellular Calcium Concentration ([Ca2+]i) in MCF-7 Breast Cancer Cells
Next Article in Special Issue
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Previous Article in Journal
Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
Previous Article in Special Issue
Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin
Article Menu

Export Article

Open AccessReview
Cancers 2014, 6(4), 2224-2242;

Highlights of the Latest Advances in Research on CDK Inhibitors

CALIPHO Group, Swiss Institute of Bioinformatics, CMU-1, rue Michel Servet' Geneva 4 CH-1211, Switzerland
MAP Kinase Resource, Bern CH-3027, Switzerland
Proteomics Centre, Vilnius University Institute of Biochemistry, Vilnius LT-08662, Lithuania
Systems Biomedicine Division and Department of Virology and Immunology, Haffkine Institute for Training Research and Testing, Mumbai 400 012, India
Nature Research Centre, Vilnius LT-08412, Lithuania
Author to whom correspondence should be addressed.
Received: 25 July 2014 / Revised: 30 September 2014 / Accepted: 14 October 2014 / Published: 27 October 2014
(This article belongs to the Collection Kinases and Cancer)
Full-Text   |   PDF [637 KB, uploaded 27 October 2014]   |  


Uncontrolled proliferation is the hallmark of cancer and other proliferative disorders and abnormal cell cycle regulation is, therefore, common in these diseases. Cyclin-dependent kinases (CDKs) play a crucial role in the control of the cell cycle and proliferation. These kinases are frequently deregulated in various cancers, viral infections, neurodegenerative diseases, ischemia and some proliferative disorders. This led to a rigorous pursuit for small-molecule CDK inhibitors for therapeutic uses. Early efforts to block CDKs with nonselective CDK inhibitors led to little specificity and efficacy but apparent toxicity, but the recent advance of selective CDK inhibitors allowed the first successful efforts to target these kinases for the therapies of several diseases. Major ongoing efforts are to develop CDK inhibitors as monotherapies and rational combinations with chemotherapy and other targeted drugs. View Full-Text
Keywords: cancer; kinase; CDK; small molecule inhibitors cancer; kinase; CDK; small molecule inhibitors

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Cicenas, J.; Kalyan, K.; Sorokinas, A.; Jatulyte, A.; Valiunas, D.; Kaupinis, A.; Valius, M. Highlights of the Latest Advances in Research on CDK Inhibitors. Cancers 2014, 6, 2224-2242.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top